Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desmethylclomipramine (also known as norclomipramine) is the primary active metabolite of the tricyclic antidepressant clomipramine. While the parent drug clomipramine is a potent serotonin reuptake inhibitor, desmethylclomipramine primarily acts as a potent inhibitor of the norepinephrine transporter (NET). In addition to its psychotropic properties, recent research has highlighted its role as an autophagy inhibitor. In the context of oncology, specifically renal cell carcinoma (RCC), desmethylclomipramine is being investigated for its ability to potentiate the anti-cancer activity of tyrosine kinase inhibitors like sunitinib. By inhibiting autophagy, it helps overcome therapeutic resistance and modulates the p53/p21 signaling pathway to induce cell cycle arrest and apoptosis in cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desmethylclomipramine.